Real-world PCSK9i Data in FH Reveal Conundrum of Reimbursement Real-world PCSK9i Data in FH Reveal Conundrum of Reimbursement

Real-world analysis shows evolocumab is as effective as in clinical trials of familial hypercholesterolemia, but high baseline LDL and lack of statins underline issues of reimbursement for PCSK9is.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Cardiology News Source Type: news